Dr. Hamburg, but in the second paragraph of your letter last December, you talked about, 'Importing non-FDA-approved drugs represents four potential risks.' No one is talking about importing non-FDA-approved drugs.
Dorgan clarifies that the discussion is about FDA-approved drugs, not non-approved ones.
Share
More from Byron Dorgan
I just want to say that I am concerned about the court's decision in Carcieri and the impact it may have on those tribes that were recognized after 1934.
I am happy to do that. I think what she and Senator Murkowski have introduced has great merit.
I wanted to say one of my regrets is I don't think we do enough in our Congress of oversight hearings.
Other voices in this conversation
